Free Trial

Nuvation Bio (NUVB) Competitors

Nuvation Bio logo
$4.85 +0.46 (+10.48%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$4.86 +0.01 (+0.10%)
As of 10/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NUVB vs. ARWR, ACLX, AKRO, CRNX, MENS, NAMS, KYMR, SRRK, VKTX, and MIRM

Should you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Jyong Biotech (MENS), NewAmsterdam Pharma (NAMS), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Viking Therapeutics (VKTX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

Nuvation Bio vs. Its Competitors

Nuvation Bio (NYSE:NUVB) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Nuvation Bio presently has a consensus price target of $7.86, suggesting a potential upside of 62.00%. Arrowhead Pharmaceuticals has a consensus price target of $43.14, suggesting a potential upside of 13.53%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Arrowhead Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvation Bio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
Arrowhead Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.78

Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Nuvation Bio's net margin of -1,413.43%. Arrowhead Pharmaceuticals' return on equity of -40.91% beat Nuvation Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvation Bio-1,413.43% -46.14% -36.04%
Arrowhead Pharmaceuticals N/A -40.91%-11.62%

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 29.9% of Nuvation Bio shares are held by insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nuvation Bio has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation Bio$7.87M210.93-$567.94M-$0.63-7.70
Arrowhead Pharmaceuticals$3.55M1,479.97-$599.49M-$1.28-29.69

Nuvation Bio has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

In the previous week, Arrowhead Pharmaceuticals had 3 more articles in the media than Nuvation Bio. MarketBeat recorded 8 mentions for Arrowhead Pharmaceuticals and 5 mentions for Nuvation Bio. Arrowhead Pharmaceuticals' average media sentiment score of 1.05 beat Nuvation Bio's score of 0.02 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nuvation Bio
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arrowhead Pharmaceuticals
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Nuvation Bio beats Arrowhead Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Nuvation Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NUVB vs. The Competition

MetricNuvation BioMED IndustryMedical SectorNYSE Exchange
Market Cap$1.50B$3.43B$6.24B$22.01B
Dividend YieldN/A2.27%5.71%3.57%
P/E Ratio-7.7025.3030.4633.26
Price / Sales210.93510.44595.1393.10
Price / CashN/A45.5737.0124.54
Price / Book3.5410.4012.044.66
Net Income-$567.94M-$52.62M$3.32B$1.01B
7 Day Performance42.23%2.09%1.88%2.19%
1 Month Performance61.40%12.32%7.68%2.04%
1 Year Performance121.46%14.12%56.01%13.99%

Nuvation Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NUVB
Nuvation Bio
2.3298 of 5 stars
$4.85
+10.5%
$7.86
+62.0%
+111.3%$1.50B$7.87M-7.7060
ARWR
Arrowhead Pharmaceuticals
3.6891 of 5 stars
$36.25
+2.4%
$43.14
+19.0%
+90.7%$4.90B$3.55M-28.32400Positive News
Analyst Forecast
Analyst Revision
ACLX
Arcellx
2.6617 of 5 stars
$86.23
-0.7%
$112.69
+30.7%
-2.1%$4.81B$107.94M-25.2180News Coverage
Positive News
Analyst Forecast
AKRO
Akero Therapeutics
3.8122 of 5 stars
$53.66
-0.4%
$73.38
+36.7%
+87.0%$4.31BN/A-26.8330Positive News
Analyst Forecast
CRNX
Crinetics Pharmaceuticals
4.2043 of 5 stars
$44.43
-1.1%
$74.45
+67.6%
-30.2%$4.23B$1.04M-10.81210Analyst Forecast
MENS
Jyong Biotech
N/A$55.70
+0.8%
N/AN/A$4.20BN/A0.0031
NAMS
NewAmsterdam Pharma
3.4093 of 5 stars
$37.15
+0.3%
$42.00
+13.1%
+89.4%$4.17B$45.56M-22.934Analyst Revision
High Trading Volume
KYMR
Kymera Therapeutics
1.385 of 5 stars
$59.89
+4.7%
$61.26
+2.3%
+20.2%$4.09B$47.07M-17.26170News Coverage
Upcoming Earnings
Analyst Forecast
Gap Up
SRRK
Scholar Rock
4.4686 of 5 stars
$34.28
-13.1%
$47.00
+37.1%
+2.3%$3.79B$33.19M-11.78140High Trading Volume
VKTX
Viking Therapeutics
4.0427 of 5 stars
$33.91
+1.0%
$86.42
+154.8%
-53.0%$3.77BN/A-22.1620Trending News
Earnings Report
Analyst Downgrade
Analyst Revision
Gap Up
MIRM
Mirum Pharmaceuticals
3.7498 of 5 stars
$72.17
-0.7%
$76.50
+6.0%
+77.9%$3.65B$336.89M-59.64140

Related Companies and Tools


This page (NYSE:NUVB) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners